Recent research has identified several agents—such as dapansutrile,febuxostat, the selective RyR2 inhibitor ent-verticilide, and propafenone, thatcan reduce AF susceptibility [147, 148, 149]. This evidence concerns the gene RYR2 and atrial fibrillation.